Phenomix Sciences cover feature

Phenomix Sciences

Mayo Clinic startup personalizing weight loss
$338,418 Raised
Ended March 15th
228 Investors

Only 30% of patients respond well to a given obesity treatment, but typical treatment is ad hoc, wasting precious time and money. As Mayo Clinic obesity doctors, we've demonstrated that identifying a patient's specific type (aka phenotype) of obesity and personalizing their treatment produces twice the amount of weight loss. With exclusive tech from Mayo Clinic, we are commercializing our first product in the form of a simple blood test to bring forward precision medicine to weight-loss therapy.

Why you may want to invest
  1. Our tech helps patients double their weight loss with fewer side effects than conventional interventions (i.e. diet, meds, devices, surgery.)

  2. Founded by 2 obesity doctors using exclusive tech from Mayo Clinic (patents pending).

  3. The blood test has been clinically validated in 2 randomized controlled Mayo Clinic trials to predict obesity drug response at 90% accuracy.

  4. Large market: over 40% of adults in the U.S. are obese).

  5. People spend thousands of dollars each year trying to lose weight with no luck.

  6. Projected price will be $600, competitively priced among other DNA tests with wellness/health coaching (range from $200 - $1000). 

  7. The Phenomix "PhenoTest" will help patients and their healthcare providers choose the most effective treatment, based on their unique biology, the first time.

  8. Provisional patent on IP for blood test and phenotyping algorithms.

Learn more about this company

Company Details

Location
Rochester, MN
Founded
2017
Employees
1

Key Team Members

Sean McCauley
Senior Advisor
Andres Acosta
MD, PhD

Financials

Most recent Fiscal Year

Income Statement

Revenue
$0
Cost of Goods Sold
$0
Gross Profit
$0
Taxes
$0
Net Income
213%
-$21,503

Balance Sheet

Total Assets
242%
$22,617
Cash
242%
$22,617
Accounts Receivable
$0
Short Term Debt
$0
Long Term Debt
$0

Other popular startups

Get email updates for the latest investment opportunities
Email
Email